Leukocyte Adhesion Deficiency Type I Market Outlook

Thelansis’s “Leukocyte Adhesion Deficiency Type I Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Leukocyte Adhesion Deficiency Type I treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Leukocyte Adhesion Deficiency Type I Overview

Leukocyte Adhesion Deficiency Type I (LAD-I) is a rare, life-threatening primary immunodeficiency caused by autosomal recessive mutations in the ITGB2 gene. This gene encodes the CD18 subunit of β2 integrins, resulting in deficient leukocyte adhesion to the vascular endothelium and the failure of neutrophil extravasation to sites of infection, despite markedly elevated peripheral blood neutrophil counts. Disease severity is stratified by residual CD18 expression—severe (<1%), moderate (1–10%), and mild (>10%)—with severe LAD-I being near-uniformly fatal in childhood without intervention. Clinically, the disease presents in the neonatal period with delayed umbilical cord separation, omphalitis, recurrent severe bacterial and fungal infections, poor wound healing, and a hallmark absence of pus formation at infection sites. Diagnosis is confirmed by flow cytometry demonstrating reduced or absent CD18 and CD11b expression on neutrophils (which normally form the critical Mac-1/CR3 integrin complex), supported by ITGB2 molecular genetic testing. Allogeneic HSCT has historically been the only curative option, though it is severely limited by donor availability, graft failure, and graft-versus-host disease. More recently, lentiviral vector-based gene therapy has emerged as a transformative therapeutic strategy. Marnetegragene autotemcel (marne-cel; Kresladi)—an autologous CD34+ hematopoietic stem cell therapy transduced with a self-inactivating lentiviral vector containing human ITGB2—demonstrated 100% overall survival, a meaningful reduction in serious infections, and improved wound healing in phase 1/2 clinical studies. With an impending FDA PDUFA date in March 2026, this one-time therapy represents a practice-changing, curative-intent advance for patients lacking a suitable transplant donor.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources &amp; assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)